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Transient anhedonia phenotype 
and altered circadian timing of 
behaviour during night-time dim 
light exposure in Per3−/− mice, but 
not wildtype mice
Bruno Jacson Martynhak1,2, Alexandra L. Hogben1, Panos Zanos1, Polymnia Georgiou1, 
Roberto Andreatini3, Ian Kitchen1, Simon N. Archer1, Malcolm von Schantz1, Alexis Bailey1,4 & 
Daan R. van der Veen1
Industrialisation greatly increased human night-time exposure to artificial light, which in animal models 
is a known cause of depressive phenotypes. Whilst many of these phenotypes are ‘direct’ effects of light 
on affect, an ‘indirect’ pathway via altered sleep-wake timing has been suggested. We have previously 
shown that the Period3 gene, which forms part of the biological clock, is associated with altered 
sleep-wake patterns in response to light. Here, we show that both wild-type and Per3−/− mice showed 
elevated levels of circulating corticosterone and increased hippocampal Bdnf expression after 3 weeks 
of exposure to dim light at night, but only mice deficient for the PERIOD3 protein (Per3−/−) exhibited 
a transient anhedonia-like phenotype, observed as reduced sucrose preference, in weeks 2–3 of dim 
light at night, whereas WT mice did not. Per3−/− mice also exhibited a significantly smaller delay in 
behavioural timing than WT mice during weeks 1, 2 and 4 of dim light at night exposure. When treated 
with imipramine, neither Per3−/− nor WT mice exhibited an anhedonia-like phenotype, and neither 
genotypes exhibited a delay in behavioural timing in responses to dLAN. While the association between 
both Per3−/− phenotypes remains unclear, both are alleviated by imipramine treatment during dim 
night-time light.
Night-time exposure to light has increased as a consequence of the use of electrical illumination in industrialised 
societies1,2. This mistimed light exposure is associated with alterations in mood and affect, and is accompanied by 
changes in sleep and circadian rhythms3. Sleep-wake timing is driven by timing of internal circadian clocks, and 
at the same time is also directly altered by light exposure. It remains unclear whether the contribution of changes 
in circadian clocks to the aetiology of mood disorders is only negative, or whether changes in sleep-wake timing 
are also a positive response, aimed at sheltering from activity-related light exposure at times when the circadian 
system is most sensitive to light4.
Changes in mood and depression are often associated with circadian rhythm disturbances such as dampen-
ing5 or loss6 of core body temperature rhythms, arguing for an indirect aetiology of mood disorders via circadian 
timekeeping mechanisms. A striking example of this indirect effect of light on mood is seasonal affective disorder, 
which is characterised by altered circadian timing and associated depressive episodes during the short photo-
periods of winter and recovery of affect under long photoperiods in the summer7,8. However, the mechanisms 
involved with altered circadian timing in the pathophysiology of mood disorders are unclear, and it remains pos-
sible that light-induced changes in mood occur independently of the changes in circadian timing.
Light is perceived through rod and cone photoreceptor pathways, as well as through the more recently 
identified non-visual pathway involving intrinsically photosensitive retinal ganglion cells (ipRGC), expressing 
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melanopsin9. In the last few years, a direct, ipRGC-dependent, pathway has been demonstrated, whereby light 
can cause mood and cognitive disruption without changes in sleep or circadian timing10. Indeed, mice that lack 
the melanopsin-expressing ipRGCs (Opn4aDTA/aDTA) do not exhibit impaired mood during exposure to a short 7-h 
light:dark cycle (3.5:3.5 h), despite them having intact image forming pathways11. These findings suggest that the 
often-observed changes in circadian timing system caused by mistimed light exposure may not be directly causal 
to the changes in affect.
In animal models of depression caused by mistimed light exposure, both constant darkness12 and con-
stant light13–15 have been shown to increase immobility in the forced swim test and reduce sucrose preference, 
both of which are measures of depressive-like behaviour. Moreover, neonatal exposure to constant light pre-
vents circadian arrhythmicity and depressive-like behaviour induced by constant light exposure in subsequent 
adulthood13,16,17, further suggesting an indirect role of light through the disruption of the circadian rhythms. 
Depressive-like behaviour induced by constant light was partially rescued when mice were given the opportunity 
to shelter from light in an opaque tube14, which suggests a role for the direct effect of the light in the development 
of mood. However informative, these experiments involving constant light conditions lead to loss of light-dark 
synchronised circadian cycles, and do not model the altered circadian timing observed in the human condition.
More recently, naturalistic approaches have been used such as exposure to short photoperiods18 and, in par-
ticular, exposure to dim light during the dark phase19. A main advantage of this “dim light at night” (dLAN) 
approach is that, under these conditions, animals remain synchronised to a 24-hour cycle, allowing the investiga-
tion of any putative changes in diel timing relative to an external light-dark cycle. Prolonged exposure to dLAN 
promotes depressive-like behaviour in various species20–22 and associates with neurobiological alterations such 
as increased hippocampal TNF-α 20, decreased hippocampal BNDF levels21, and decreased hippocampal CA1 
dendritic arborisation19.
In order to understand what role light-associated changes in circadian timing play in the onset of 
depressive-like behaviour in dLAN, we turned to the Per3-deficient (Per3−/−) mouse model. Mice lacking 
PERIOD3 are synchronised to light:dark cycles in a normal way, and exhibit normal immediate responses to 
light-induced phase shifts23. While these aspects of the circadian system are thus intact in Per3−/− mice, they 
exhibit reduced behavioural circadian responses to constant light, and show less negative masking of behaviour 
by light (i.e., less activity inhibition by light)24,25. Because of this previously described phenotype, in which Per3−/− 
mice exhibit an attenuated circadian response to prolonged light exposure, this rodent model can be used to 
investigate the development of mood disorders mediated by light at night, owing to the increased direct changes 
in behavioural timing in response to light, rather than indirect effects via the circadian system in the mice.
We hypothesise that if the circadian system is part of the pathophysiology of mood disorders in dLAN, 
Per3−/− mice would exhibit an altered time of onset of anhedonia-like behaviour than wild-type (WT) mice 
do. We observed that Per3−/− mice showed both a reduced delay in circadian timing of behaviour in weeks 1, 
2 and 4 of night-time dim light exposure, and a transient reduction of sucrose preference in weeks 2 and 3 of 
night-time dim light exposure. The anhedonia-like phenotype as measured in our sucrose preference test is asso-
ciated with a depressive-like phenotype26. The nature of the association between these changes in behaviour and 
anhedonia-like responses in Per3−/− mice remains unclear, but imipramine treatment alleviates both phenotypes 
of Per3−/− mice in response to dim light at night.
Results
Baseline phenotype in the Forced Swim test. Neither total immobility (Fig. 1A) nor latency to the 
first immobility (Fig. 1B) were significantly different between the genotypes (t = 1.09, p > 0.05) and (t = 0.67, 
p > 0.05).
Sucrose preference. At the end of the second week of dLAN, Per3−/− mice, but not wild type mice, exhib-
ited a significantly reduced sucrose preference. Figure 2A shows that this reduced sucrose preference remained 
significantly reduced during week 3, and then returned to the same levels as the WT mice (genotype: F1,27 = 27.90, 
p < 0.001; light schedule: F1,27 = 1.42, p > 0.2; genotype x light condition: F1,27 = 5.19; p < 0.05; genotype x light 
schedule x week: F4,108 = 18.3, p < 0.001).
In a second experiment, we confirmed a reduction of sucrose preference in Per3−/−, which was not observed 
in wild type mice, in week 2 and 3 after the start of dLAN. Treatment with the tricyclic antidepressant imipramine 
prevented the development of reduced sucrose preference in the Per3−/− mice (Fig. 2B, genotype: F1,26 = 10.0, 
p < 0.01; treatment: F1,26 = 0.9, p > 0.2; genotype x treatment: F1,26 = 5.5, p < 0.05; genotype x treatment x 
week: F3,78 = 4.2, p < 0.01). Post hoc analysis showed that sucrose preference was significantly reduced during 
weeks 2 and 3 of dLAN exposure in Per3−/− mice that received no imipramine treatment (p < 0.001), but not in 
imipramine-treated Per3−/−mice (Fig. 2B).
Timing of behavioural activity. During light-dark entrained conditions, there was no difference in the 
timing of behavioural activity of WT and Per3−/− mice, as measured by the timing of the first and second peak 
of nocturnal behavioural activity, but a timing difference between genotypes was observed when the mice were 
exposed to dLAN (PROC MIXED, genotype: F1,233 = 4.59; dLAN: F1,233 = 25.75; treatment: F1,233 = 6.34; genotype 
x dLAN: F1,233 = 10.47 ; genotype x treatment: F1,233 = 5.83; p < 0.05). Supplemental Figure 1 shows average activ-
ity profiles and respective average Fourier fits for each week during baseline, dLAN and dLAN with imipramine 
conditions for both wild-type and Per3−/− mice. Figure S2 shows example actogram of WT and Per3−/− going 
through a dim light at night protocol without, and with Imipramine.
Figure 3A shows that both WT and Per3−/− mice exhibit stable and invariant timing of behavioural activity 
peaks in light-dark entrained conditions (LSMEANS p > 0.05). Figure 3B shows a similar entrainment patterns 
in the baseline week, but during the exposure to dLAN, the Per3−/− mice showed an attenuated delay in timing of 
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the first behavioural activity peak (LSMEANS p < 0.05 in weeks 1, 2 and 4 of dLAN), indicating that Per3−/− mice 
were more active in the early night than WT mice are under these conditions.
Imipramine treatment resulted in similar timing of behavioural activity between WT and Per3−/− mice in both 
the baseline and dLAN conditions (Fig. 3C, LSMEANS P > 0.05). Importantly, imipramine treatment prevented 
the dLAN-induced phase delay in week 2 (LSMEANS p < 0.05), whereas imipramine treatment in WT mice pre-
vented the phase delay in weeks 3 and 4 (p < 0.001).
Although not plotted in a single graph, dLAN phase delayed the second peak of activity similarly in Per3−/− 
and WT mice (LSMEANS P < 0.0001, Fig. 3B,C), an effect that was rescued by imipramine treatment (LSMEANS 
p < 0.05).
Circulating corticosterone levels. As shown in Fig. 4, plasma corticosterone levels were increased in both 
genotypes after dLAN exposure with and without imipramine treatment (group: F2,36 = 19.72, p < 0.001; gen-
otype: F1,36 = 1.35, p > 0.05, genotype x group: F2,36 = 0.56; p > 0.05). The level of plasma corticosterone in the 
imipramine-treated mice was intermediate to that of the light-dark entrained mice and the dLAN treated mice 
without imipramine (p < 0.05).
Figure 1. Immobility time (A) and latency to immobility (B) in the Forced Swim test in WT and Per3−/− mice. 
Data is shown as histograms of means and standard error of the mean, circles indicate individual values. 
n = 8–12 males per group.
Figure 2. Sucrose preference in WT and Per3−/− mice in (A) LD or dim light at night and (B) dim light at night, 
treated with tap water or imipramine in the drinking water. Values are presented as means and standard error of 
the mean. †p < 0.05 in comparison with the control group. ‡p < 0.05 in comparison with baseline. n = 6–8 males 
per group.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:40399 | DOI: 10.1038/srep40399
Hippocampal gene expression. Bdnf expression in the hippocampus was increased in both genotypes 
after dLAN exposure with, and without imipramine treatment (Fig. 5), but the level of hippocampal Bdnf expres-
sion in the imipramine-treated mice was intermediate to that of the light-dark entrained mice and the dLAN 
treated mice without imipramine (group: F2,35 = 4.32, p < 0.05; genotype: F1,35 = 2.23, p > 0.05, genotype x group: 
F2,35 = 0.52; p > 0.05).
For the hippocampal Tnf-α expression, a significant interaction between genotype and group was found 
(F2,30 = 3.99, p < 0.05). However, post hoc analysis did not reveal any significant contrasts.
Discussion
We have shown that, after two weeks of exposure to dim light at night, mice deficient in the PERIOD3 protein 
develop an anhedonic-like phenotype. Both wild type and Per3−/− mice exhibited increased levels of circulating 
corticosterone and hippocampal Bdnf expression in response to dim light at night. The rapid development of a 
reduced sucrose preference phenotype in Per3−/− mice in the second week after exposure to dim light at night, 
was much earlier than normally expected, as it has been well documented that after two weeks of dim light 
at night, mice normally do not develop a depressive-like phenotype14,19–21,27. The early onset of this transient 
anhedonia-like phenotype in weeks 2 and 3 of dim light at night, partially overlapped with the significant attenu-
ation in the behavioural phase delay during weeks 1, 3, and 4 of this dim light at night protocol. Per3−/− mice did 
not delay their behavioural activity onset as much as wild type mice do during these weeks, which is in line with 
our previously published observations24,25. The weeks in which Per3−/− mice exhibit this significant attenuation 
in the delay in activity in comparison with WT mice did not match entirely with weeks in which Per3−/− mice 
showed reduction in sucrose preference, and we have no evidence for a causal relationship. Interestingly, a recent 
publication shows that mice carrying a humanised Per3 transgene similarly exhibit a depressive-like phenotype, 
as well as changes in the molecular circadian clock28.
Anhedonia, defined as a diminished ability to experience pleasure in previously rewarding stimuli, is widely 
considered as a core symptom of human depression29–32. Importantly, more than half of the individuals suffering 
from bipolar depression also experience significant levels of anhedonia33, and depressed patients with reported 
Figure 3. Phase of activity of the first and second peaks of activity. (A) LD. (B) dLAN (C) dLAN and 
imipramine treatment. *p < 0.05 in comparison with WT. Circles represent mean and standard error of the 
mean of the first and second peaks of activity, areas indicate time between both peaks. Grey areas: dim light at 
night, dark grey areas: dark phase of the cycle. n = 6–8 males per group.
Figure 4. Plasma corticosterone collected at ZT0 (lights on). Mice were killed at the end of week 4 for LD 
and week 3 for dLAN. Data is shown as histograms of means and standard error of the mean, circles indicate 
individual values. n = 5–8 males per group. *p < 0.05.
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anhedonia have a poorer treatment prognosis than their non-anhedonic counterparts34–36, highlighting the sig-
nificant role of anhedonia in these affective disorders. In animal models of depression, hedonic deficits, and more 
specifically decreased sucrose preference, can be induced by chronic stress37–40, chronic social defeats41,42 and 
chronic administration of corticosterone43–45. All these models have been shown to induce biochemical changes 
similar to those observed in depressed patients46–49.
In line with this association of reduced sucrose preference with a depressive-like phenotype, pharmacological 
treatment with the antidepressant imipramine prevented the development of the anhedonia-like behaviour in 
Per3−/− mice, similarly to the reported effect of citalopram in preventing increased immobility in the FST test 
in WT mice exposed to dLAN50. Imipramine treatment also reduced the delay in the circadian activity in both 
Per3−/− and WT mice. Whether the imipramine-associated change in the behavioural response of Per3−/− mice 
in dLAN is part of the mode of action of this antidepressant is unclear, but imipramine treatment in itself was 
reported not to change any measure of the circadian rhythms in naïve hamsters51, suggesting that it may act 
upstream of the circadian clock in relation to mood regulation, which has been suggested before, even though 
ambiguously51–54. It is unclear what from this study whether there are underlying mechanisms which may link 
timing of behavioural activity in dLAN to reduction in sucrose preference, but it may be hypothesised that delay-
ing the activity bout reduces light exposure during activity in the early night, when the circadian system responds 
strongly to light4,55.
In a previous study using wild type mice, dim light at night triggered depressive-like behaviour only after four 
weeks of night time light exposure21, also measured as sucrose anhedonia and the forced swim test. The absence 
of a sucrose anhedonia in wild type mice during the four weeks of dLAN that we used is therefore expected, and 
the transient reduction of sucrose preference in our Per3−/− mice is uncharacteristically rapid. In the fourth week 
of dLAN, the reduction in sucrose preference in the Per3−/− mice spontaneously subsided. Whilst some variabil-
ity in sucrose preference is commonly observed during a chronic mild stress model, including the spontaneous 
recovery during the chronic stress56, it is unclear why the early onset of anhedonia-like phenotype of Per3−/− mice 
subsides at in week 4 during dLAN exposure. This spontaneous recovery could be part of the ongoing long-term 
changes in affect, which also result in the development of depressive-like behaviour in WT rodents only after 4–8 
weeks14,19–21,27.
C57bl/6 mice do not produce significant rhythms in melatonin57, in contrast to the C3H/HeNHsd mice used 
in the previous work linking dim light at night to the development of depressive-like behaviour21. Therefore, pro-
posed pathways whereby suppression of melatonin production through dim light may add to the anhedonia-like 
phenotype effects of dLAN are unlikely to be functional in our model, and the results obtained here point to 
mechanisms independent from melatonin.
Prolonged dLAN exposure increased plasma corticosterone levels and hippocampal Bdnf levels in both 
wild-type and Per3−/− mice, irrespective of the affective state of the animals, and imipramine treatment attenu-
ated the increase in both. Several stressors, which increase corticosterone, can be used to promote depressive-like 
behaviour in rodents39 and exogenous corticosterone can also lead to depressive-like behaviour58. Although 
chronic stress usually leads to reduction of BDNF58, in our study, Bdnf expression was increased after dLAN 
exposure. However, an increase in hippocampal Bdnf expression does not necessarily reflect increased activation 
of its receptor, TrkB. It is known that pro-BDNF, when not converted to BDNF, may actually lead to opposite 
Figure 5. Expression of hippocampal Bdnf (A) and hippocampal Tnf-α (B). Data is shown as histograms of 
means and standard error of the mean, circles indicate individual values. Mice were killed at the end of week 4 
for LD and week 3 for dLAN. n = 5-8 males per group. *p < 0.05.
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effects on BDNF, inducing apoptosis instead of cell survival59. An increase in pro-BDNF may be what is reflected 
by the increase in hippocampal Bdnf expression after exposure to dLAN. In addition, early life stress increased 
Bdnf expression and neurogenesis in young adults, but decreased in aged rats60. One could thus interpret that our 
changes in bdnf expression and circulating corticosterone levels represent early activation of the peripheral stress 
system, which is a prelude to a depressive-like phenotype that has been reported to occur later21, and are unrelated 
to the early onset sucrose-anhedonia phenotype linked to behavioural timing described here. However, it should 
be noted that a single time point (ZT0) was used for the analysis, and the possibility of differences at other time 
points cannot be excluded.
Levels of hippocampal Tnf-α expression varied significantly between imipramine treatment and genotypes, 
and although we may suspect an increase in hippocampal Tnf-α expression in Per3−/− mice that is associated 
with their anhedonia-like behaviour in dLAN, no significant differences could be identified using post hoc tests. 
Depression has been widely associated with increased inflammatory processes61, with anti-inflammatory drugs 
having antidepressant-like effects in the chronic mild stress model in rats62 and being used as an add-on therapy 
for major depression63. As it stands though, our data does not confirm that inflammation plays a particular role 
in early onset of the sucrose anhedonia induced by dLAN in Per3−/− mice.
One limitation of this study is that we chose to only pursue sucrose preference for evaluation of the 
depressive-like behaviour, and discontinued the forced swim test after the baseline measurements, which showed 
immobility times in line with previously published work64,65. The sucrose preference test is less stressful than other 
frequently used tests, such as forced swim test and tail suspension test, and is more appropriate for repeated meas-
urements in chronic studies. Moreover, the ‘acute’ nature of the forced swim test and tail suspension test would 
only allow us a measurement at a single circadian time point, and due to the stress associated with these tests may 
even act as a circadian timing signal which would confound our current approach. The sucrose preference test 
is related to anhedonia, which is a core symptom of major depression26, and while the forced swim test is most 
frequently used to screen putative antidepressant-like drugs, we really do not know what it measures: despair, 
hopeless or an adaptive behaviour for energy conservation66.
We have shown that Per3−/− mice rapidly develop a transient anhedonic-like phenotype, as well as an attenu-
ated delay in the sleep-wake timing during dim light at night as compared to wild-type mice. This early onset of 
reduced sucrose preference in Per3−/− mice was prevented by imipramine treatment, which also prevented the 
delay in behavioural activity under dLAN in both wild type and Per3−/− mice. These Per3−/− specific changes in 
measures associated with affect appear unrelated to the general levels of stress caused by dim light at night, as 
measured by hippocampal Bdnf expression and circulation corticosterone in both genotypes. While the associ-
ation between the anhedonia-like phenotype and changes in behavioural timing remains unclear, both Per3−/− 
phenotypes are alleviated by imipramine treatment during dim night-time light.
Materials and Methods
Ethics statement. All mouse experimental procedures were approved by the U.K. Home Office. All mouse 
experiments were carried out in accordance with the guidelines and regulations of the U.K. Home Office.
Subjects and housing. All mice were backcrossed to a C57BL/6J genetic background for at least 10 gen-
erations. Mice homozygous for a targeted disruption of the Per3 gene23, and their wild-type controls were bred 
in-house from heterozygous breeding pairs and genotyped as published elsewhere24. All experiments were per-
formed with male mice. Food and water were available ad libitum. Individual cage illumination was supplied by 
LEDs (NSPW500BS, Nichia Europe BV, Amsterdam, the Netherlands) through frosted glass. Light intensity was 
measured with the light-sensor at the cage bottom directed toward the light.
For the Forced Swim test, mice were housed in groups of 2–5 per cage in a temperature-controlled environ-
ment with a 12:12-h light/dark cycle (150 lux in light phase, light on at: 07:00 h GMT).
For dLAN experiment, adult (8 weeks old) mice were individually housed in light-tight, sound-attenuated 
cabinets. Home cage locomotor activity was continuously recorded through passive infrared detectors (Gardtec 
Gardscan MX PIR, Gardiner Technology, Rochdale, UK) connected to a PC (ClockLab, Actimetrics, Wilmette, IL), 
and analysed in 1-minute bins. Animals were kept in 12:12-h light/dark cycle (150 lux for light phase, lights on: 
10:00 h).
Forced Swim test. To evaluate whether Per3-deficient mice had a different anhedonia-like phenotype than 
WT mice under baseline conditions, the Forced Swim test was performed as previously published67. Briefly, ani-
mals were manually handled for habituation for three consecutive days previous to testing between ZT2 and ZT6. 
On the testing day, animals were placed in a transparent cylinder of water at 23–24 °C for 6 min with environmen-
tal light levels of 40 lux, again at ZT2-ZT6 Total immobility time, and latency to the first immobility episode were 
scored as measures of depressive-like behaviour.
Dim light at night (dLAN). After two weeks of acclimation under 12:12-h light/dark cycle (150 lux in light 
phase, lights on at 10:00 h) and single housing, a baseline sucrose preference test (described below) was performed 
and mice were randomly assigned to remain in either a LD cycle, or assigned to the dim light at night cycle (150 
lux in light phase, 5 lux in dim light phase, brighter lights on at 10:00 h, 7–8 mice per group)21. Sucrose preference 
tests were performed weekly to evaluate the time-course for the development of any depressive-like behaviour. 
After four weeks mice from the LD group were killed at ZT0, and trunk blood was collected in heparin-coated 
tubes for corticosterone measurements, and brains were collected in RNAlater (Sigma Aldrich, St Louis, MO) and 
frozen at − 80 °C for subsequent dissection and qPCR. Since there was spontaneous recovery from the reduction 
in sucrose preference, only the control (LD) mice had their tissue collected in this experiment.
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dLAN with imipramine treatment. In order to investigate whether the dLAN-induced depressive-like 
behaviour was rescued trough antidepressant treatment, a second experiment was performed similarly to the first 
one. In this experiment, following two weeks of 12:12-h light/dark cycle, mice were assigned to a control group 
(dLAN only), or the imipramine treatment group (6–8 mice per group). All mice were exposed to the dLAN cycle 
and killed at the end of week 3 (at this time there was a significant reduction in sucrose preference in the Per3−/− 
mice under dLAN without imipramine treatment), and blood and tissues were collected for analysis. Imipramine 
pre-treatment started two weeks before the onset of dLAN and continued throughout the experiment in order 
to prevent the dLAN-induced reduction in sucrose preference [it has been reported that 7 days of imipramine 
pre-treatment through drinking water could prevent stress-induced anhedonia68].
In order to minimise disturbances to the animal, imipramine was offered through the drinking water at a con-
centration of 128 mg/L. Based on a body mass of ~30 g, and a consumption of ~3.5 mL of water per day, this would 
result in a dose of 10–15 mg/kg imipramine per day. This schedule of treatment was previously used by members 
of our group with the same target dose in rats13
Sucrose preference test. The sucrose preference test was performed as previously published39,69, with 
minor modifications. Mice were offered free choice of two drinking bottles, one containing tap water, and the 
other containing a 2% sucrose solution in tap water. After 24 hours (from ZT23 to ZT23, to avoid unneeded 
arousal due to bottle exchange), consumption from both bottles was measured, and mice were restored to a single 
bottle containing tap water. Sucrose preference is always shown as percentage of sucrose solution intake in rela-
tion to total liquid intake. Mice were first habituated to the sucrose 7 days before the start of the dLAN schedule, 
by offering solely the sucrose solutions for 24 hours, followed by 48 hours of free choice between tap water and 
sucrose solution. The sucrose preference tests were conducted on the last day of each of the experiment, thus day 
0, 7, 14, 21 and 28, corresponding to the last day of baseline in LD, week 1, week 2, week 3 and week 4 in dLAN.
Gene expression using quantitative PCR. The hippocampus and a block of prefrontal cortex were man-
ually dissected from the brains, which had been stabilised in RNA Later (Invitrogen, CA, USA) upon collection. 
mRNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. For each sample, both the level of expression of the gene of interest and housekeeping gene (Arp) 
was performed using Taqman qPCR. The primers and probe for each gene are shown in Table 1.
Corticosterone measurement. 1–1.5 mL of trunk blood from each animal was collected in heparin-coated 
tubes, and immediately placed on ice. Samples were centrifuged at 4 °C (> 16 000 RCF) and plasma was stored at 
− 20 °C until processing. Corticosterone levels were assessed using a rat/mouse corticosterone [125I] radioimmu-
noassay kit (MP Biomedicals, New York, NY), according to the manufacturer’s instructions. The corticosterone 
levels were determined in technical duplicates, and all samples were assessed in a single assay.
Statistics. The results of the Forced Swim test were analysed using unpaired, two-tailed t-tests. Sucrose pref-
erence, corticosterone and gene expression levels were statistically tested using by 3-way ANOVA (with repeated 
measures where appropriate), with factors genotype, light condition and imipramine treatment, and individual 
as repeated measures. Where ANOVA tests indicated statistical significant effects, post hoc pairwise comparisons 
were made using the Newman-Keuls test. All tests were performed in Sigmaplot version 12.3 (Systat Software Inc, 
San Jose, CA).
Determination of circadian timing of behavioural activity started with the identification of the first and second 
peak phases of locomotor activity by means of fitting two harmonic Fourier curves through the Z-scored behav-
ioural data of the last two days of each week, for each mouse for each week. On some occasions, no first or second 
peak could be fitted due to low activity, resulting in 38 out of a potential total of 275 peaks being omitted from 
the analysis, which is a loss of less than 10%. The two separate groups of animals assigned to dLAN at different 
occasions (in the first and second experiment) did not show significant differences in any of the measures, and are 
therefore represented as a single group to increase statistical power. All statistics were performed using procedure 
MIXED in SAS 9.2 (SAS Institute, Cary, NC), and where statistical significant effects were identified, the post-hoc 
comparison was based on least square means (LSMEANS).
Results are expressed as mean ± Standard Error of the Mean (SEM).
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Target Forward Reverse Probe
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